HLA class II genes determine the natural variance of hepatitis C viral load

被引:43
作者
Fanning, LJ
Levis, J
Kenny-Walsh, E
Whelton, M
O'Sullivan, K
Shanahan, F
机构
[1] Natl Univ Ireland Univ Coll Cork, Dept Med, Hepatitis Unit C, Cork, Ireland
[2] Natl Univ Ireland Univ Coll Cork, Dept Stat, Cork, Ireland
关键词
D O I
10.1053/jhep.2001.20642
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The aim of this study was to investigate the relationship between human leukocyte antigen (HLA) class II genes and the natural fluctuations in hepatitis C viral load in a homogeneous patient population. The study group consisted of 57 viremic (hepatitis C virus [HCV] 1b) women for whom HLA class II DRB1 and DQB1 haplotyping, virologic, histologic, and biochemical markers of disease activity were available. All patients were infected with HCV 1b from the same source of hepatitis C-contaminated anti-D immunoglobulin during the period from May 1977 to November 1978, The mean slope of change of viral load was 0.34 (SD +/- 0.73) log(10) viral copies/mL/year, which is significantly different from zero, P < 10(-9). Analysis of the relationship between the slope of change of viral load and HLA class II haplotype indicated a significantly different slope of change of viral load between the alleles of (1) DRB1"15 and DRB1*0701, and (2) DQB1*0602 and DQB1*0201, P-c = .036 and P-c = .026 after Bonferroni correction for multiple comparisons, respectively. Significant differences for grade and stage of disease at liver biopsy were observed for DQB1*0501 and DQB1*0201 alleles; P = .019, r(s) = .64, and P = .047, r(s) = .57, respectively. In addition, significant differences in stage of disease were found to exist between DRB1*13 and DRB1*0701, P = .031, r(s) = -.71. Our results define an association between the slope of change of viral load and HLA class II haplotype in patients infected with genotype Ib of HCV, This suggests a role for host immunogenetic factors in HCV infection in this homogeneous group.
引用
收藏
页码:224 / 230
页数:7
相关论文
共 63 条
[41]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[42]   The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C [J].
McKiernan, SM ;
Hagan, R ;
Curry, M ;
McDonald, GSA ;
Nolan, N ;
Crowley, J ;
Hegarty, J ;
Lawlor, E ;
Kelleher, D .
GASTROENTEROLOGY, 2000, 118 (06) :1124-1130
[43]   Isolation and utilization of human dendritic cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster virus peptides [J].
Jenkins, DE ;
Yasukawa, LL ;
Benike, CJ ;
Engleman, EG ;
Arvin, AM .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 :S39-S42
[44]   Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy [J].
Neumann, AU ;
Lam, NP ;
Dahari, H ;
Gretch, DR ;
Wiley, TE ;
Layden, TJ ;
Perelson, AS .
SCIENCE, 1998, 282 (5386) :103-107
[45]   Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection [J].
Nguyen, TT ;
SedghiVaziri, A ;
Wilkes, LB ;
Mondala, T ;
Pockros, PJ ;
Lindsay, KL ;
McHutchison, JG .
JOURNAL OF VIRAL HEPATITIS, 1996, 3 (02) :75-78
[46]   Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens [J].
Papatheodoridis, GV ;
Barton, SGRG ;
Andrew, D ;
Clewley, G ;
Davies, S ;
Dhillon, AP ;
Dusheiko, G ;
Davidson, B ;
Rolles, K ;
Burroughs, AK .
GUT, 1999, 45 (03) :427-434
[47]   HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time [J].
Perelson, AS ;
Neumann, AU ;
Markowitz, M ;
Leonard, JM ;
Ho, DD .
SCIENCE, 1996, 271 (5255) :1582-1586
[48]   Natural history of liver fibrosis progression in patients with chronic hepatitis C [J].
Poynard, T ;
Bedossa, P ;
Opolon, P .
LANCET, 1997, 349 (9055) :825-832
[49]   Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus [J].
Poynard, T ;
Marcellin, P ;
Lee, SS ;
Niederau, C ;
Minuk, GS ;
Ideo, G ;
Bain, V ;
Heathcote, J ;
Zeuzem, S ;
Trepo, C ;
Albrecht, J .
LANCET, 1998, 352 (9138) :1426-1432
[50]   Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy [J].
Puchhammer-Stöckl, E ;
Mandl, CW ;
Kletzmayr, J ;
Holzmann, H ;
Hofmann, A ;
Aberle, SW ;
Heinz, FX ;
Watschinger, B ;
Hofmann, H .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :2063-2066